1437501-99-9

Basic information

• Product Name: (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt
• Synonyms: (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt
• CAS NO: 1437501-99-9
• Molecular Weight: 630.743
• Mol File: 1437501-99-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt(1437501-99-9)
• EPA Substance Registry System: (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt(1437501-99-9)

Safety Data

• Hazardous Substances Data: 1437501-99-9(Hazardous Substances Data)

Upstream product

• 1437501-98-8 (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester 
• 81-04-9 naphthalene-1,5-disulfonate 
• 1254831-46-3 (E)-2-(1-cyclohexyl-1H-imidazol-4-yl)-3-hydroxy-but-2-enedioic acid diethyl ester 
• 1254831-47-4 (1-cyclohexyl-1H-imidazol-4-yl)-acetic acid ethyl ester 
• 1254831-48-5 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester 

Downstream Products

• 1375150-73-4 (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid 

Relevant articles and documents

CRYSTALLINE SALTS OF R)-3-[6-AMINO-PYRIDIN-3-YL]-2-(1-CYCLOHEXYL-1H-IMIDAZOL-4-YL)-PROPIONIC ACID

The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1 -cyclohexyl- 1 H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).